Lipid mediator class switching during acute inflammation: signals in resolution
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Leukotrienes (LTs) and prostaglandins (PGs) amplify acute inflammation, whereas lipoxins (LXs) have unique anti-inflammatory actions. Temporal analyses of these eicosanoids in clinical and experimental exudates showed early coordinate appearance of LT and PG with polymorphonuclear neutrophil (PMN) recruitment. This was followed by LX biosynthesis, which was concurrent with spontaneous resolution. Human peripheral blood PMNs exposed to PGE2 (as in exudates) switched eicosanoid biosynthesis from predominantly LTB4 and 5-lipoxygenase (5-LO)-initiated pathways to LXA4, a 15-LO product that "stopped" PMN infiltration. These results indicate that first-phase eicosanoids promote a shift to anti-inflammatory lipids: functionally distinct lipid-mediator profiles switch during acute exudate formation to "reprogram" the exudate PMNs to promote resolution.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin E2 (PGE2) and D2 rapidly initiate the resolution process by inducing the expression of lipid mediators with both anti-inflammatory and pre-resolution functions, e.g., lipoxins [96, 97], resolvins and protectins [98–100], a process known as lipid-mediator class switch [97].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [97]
Citations
Cites
Inflammation. Basic principles and clinical correlates
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90156-x · Cited by 2,393
Inducible cyclooxygenase may have anti-inflammatory properties
Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., & Willoughby, D. A. (1999) · Nature Medicine · doi:10.1038/9550 · Cited by 1,242
Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., & Brady, H. R. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1663 · Cited by 638
Inflammation: Basic Principles and Clinical Correlates
Ehrlich, G. E. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.1.123 · Cited by 622
Shinmura, K., Tang, X.-L., Wang, Y., Xuan, Y.-T., Liu, S.-Q., Takano, H., Bhatnagar, A., & Bolli, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10197 · Cited by 381
Swan, S. K., Rudy, D. W., Lasseter, K. C., Ryan, C. F., Buechel, K. L., Lambrecht, L. J., Pinto, M. B., Dilzer, S. C., Obrda, O., Sundblad, K. J., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00002 · Cited by 339
Design of Lipoxin A4 Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils
Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., & Madara, J. L. (1995) · Biochemistry · doi:10.1021/bi00044a041 · Cited by 327
Self-citationActivation of the NF-κB Pathway by Inflammatory Stimuli in Human Neutrophils
McDonald, P. P., Bald, A., & Cassatella, M. A. (1997) · Blood · doi:10.1182/blood.v89.9.3421 · Cited by 324
Prostaglandins, Aspirin-like Drugs and the Oedema of Inflammation
MONCADA, S., FERREIRA, S. H., & VANE, J. R. (1973) · Nature · doi:10.1038/246217a0 · Cited by 312 · cited 1×
“Although PGE 2 induces reactions that mediate several of the cardinal features of inflammation (for example, edem”
BackgroundTessier, P. A., Naccache, P. H., Clark-Lewis, I., Gladue, R. P., Neote, K. S., & McColl, S. R. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3595 · Cited by 233
Research works printed but not linked: 2
- Light, R. W. Pleural Diseases (Lea & Febiger, Philadelphia, 1990).
- Clish, C. B. et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl Acad Sci USA 96, 8247–8252 (1999). · DOI · Paper page
Cited by
Items 601–700 of 1,000
Perucci, L. O., Sugimoto, M. A., Gomes, K. B., Dusse, L. M. S., Teixeira, M. M., & Sousa, L. P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1364363 · Cited by 49
“These results points to a possible dysfunction in the conversion of leukotrienes into lipoxins mediated by 15-LOX-2 enzyme, a process coined ‘lipid mediator-class switching’ (Figure 1), in the lungs of CF patients, which might be associated with persistent tissue inflammation [184,185].”
BackgroundRedox (phospho)lipidomics of signaling in inflammation and programmed cell death
Tyurina, Y. Y., Croix, C. M. S., Watkins, S. C., Watson, A. M., Epperly, M. W., Anthonymuthu, T. S., Kisin, E. R., Vlasova, I. I., Krysko, O., Krysko, D. V., et al. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0119-004rr · Cited by 49
Holopainen, M., Colas, R. A., Valkonen, S., Tigistu‐Sahle, F., Hyvärinen, K., Mazzacuva, F., Lehenkari, P. P., Käkelä, R., Dalli, J., Kerkelä, E., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.06.010 · Cited by 48
“16 [17], which merits investigation in light of the immunomodulatory response of hBMSCs [70].”
BackgroundCytochrome P450-derived eicosanoids and inflammation in liver diseases
Shoieb, S. M., El‐Ghiaty, M. A., Alqahtani, M. A., & El‐Kadi, A. O. S. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106400 · Cited by 46
Macrophage Activation in the Synovium of Healthy and Osteoarthritic Equine Joints
Menarim, B. C., Gillis, K. H., Oliver, A., Ngo, Y., Werre, S. R., Barrett, S. H., Rodgerson, D. H., & Dahlgren, L. A. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.568756 · Cited by 55
Insuela, D. B. R., Ferrero, M. R., Coutinho, D. D. S., Martins, M. A., & Carvalho, V. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580598 · Cited by 47
“Although PGE2 is a pro-inflammatory mediator, several works have shown that this lipid presents pro-resolving actions in some contexts (30).”
BackgroundZhu, J., Kilty, I., Granger, H., Gamble, E. A., Qiu, Y. S., Hattotuwa, K., Elston, W., Liu, W. L., Oliva, A., PAUWELS, R. A., et al. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.4820 · Cited by 43
Endogenous lipid-derived ligands for sensory TRP ion channels and their pain modulation
Bang, S., Yoo, S., Oh, U., & Hwang, S. W. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1004-9 · Cited by 45
Maxis, K., Delalandre, A., Martel‐Pelletier, J., Pelletier, J., Duval, N., & Lajeunesse, D. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2092 · Cited by 42
“in these animals, which is reminiscent of the fact that PGE2 inhibits 5-LO activity [55].”
BackgroundGuimarães, F. R., Sales‐Campos, H., Nardini, V., da Costa, T. Á., Fonseca, M. T., Rodrigues, V., Sorgi, C. A., Silva, J. S., Chica, J. E. L., Faccioli, L. H., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.022 · Cited by 45
Prolonged immune alteration following resolution of acute inflammation in humans
Motwani, M. P., Newson, J., Kwong, S., Richard-Loendt, A., Colas, R., Dalli, J., & Gilroy, D. W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186964 · Cited by 42
Neutrophils: Beneficial and Harmful Cells in Septic Arthritis
Boff, D., Crijns, H., Teixeira, M. M., Amaral, F. A., & Proost, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020468 · Cited by 48
“During the inflammatory process, another class of arachidonic acid (AA)-derived lipids, prostaglandins E2 and D2, induce the switch of leukotriene synthesis to pro-resolving lipid production, including lipoxin A4 (LXA4) [189,217,218].”
BackgroundFattori, V., Zaninelli, T. H., Ferraz, C. R., Brasil-Silva, L., Borghi, S. M., da Cunha, J. M., Chichorro, J. G., Casagrande, R., & Verri, W. A., Jr. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109189 · Cited by 44
Essential Polyunsaturated Fatty Acids, Inflammation, Atherosclerosis and Cardiovascular Diseases
de Lorgeril, M. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_13 · Cited by 45
Sur, R., Babad, J. M., Garay, M., Liebel, F. T., & Southall, M. D. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700972 · Cited by 41
“In human peripheral blood polymorphonuclear neutrophils, PGE2 was found to cause a switch from proinflammatory to anti-inflammatory strategy by switching eicosanoid biosynthesis from predominantly 5-lipoxygenaseinitiated leukotriene B4 production to 15-lipoxygenaseinitiated lipoxin A4 production that carry ‘‘stop sign…”
BackgroundRoles of lipid metabolism in keloid development
Huang, C., & Ogawa, R. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-60 · Cited by 41
“lipoxins by inducing 15-lipoxygenase (15-LOX) [16,17].”
Perretti, M., Ingegnoli, F., Wheller, S. K., Blades, M. C., Solito, E., & Pitzalis, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.4.2085 · Cited by 42
Resolution of inflammation in oral diseases
Eltay, E. G., & Dyke, T. E. V. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108453 · Cited by 46
Beck‐Speier, I., Karg, E. W., Behrendt, H., Stoeger, T., & Alessandrini, F. (2012) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-9-27 · Cited by 43
“This is due to the ability of PGE2 to induce 15-lipoxygenase expression for production of 15(S)-HETE thus promoting the biosynthesis of lipoxins such as LXA4 [41,42].”
BackgroundReversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degree
Wu, S., Yin, P., Zhang, Y., & Hui-xian, T. (2010) · Pediatric Pulmonology · doi:10.1002/ppul.21186 · Cited by 41
Fiala, M., Terrando, N., & Dalli, J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150367 · Cited by 41
“convert the PUFA substrate via subsequent lipoxygenation reactions [52].”
Serini, S., Vasconcelos, R. O., Fasano, E., & Calviello, G. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1139085 · Cited by 43
“as lipoxines or resolvins and protectins, described below).[50,51] Also, AA-derived PGD2 may elicit proresolving action by binding to its receptor DP1 or by being converted nonenzymatically to its bioactive derivative belonging to the J2 series.”
BackgroundGao, Y., Zhang, H., Luo, L., Lin, J., Li, D., Zheng, S., Huang, H., Yan, S.-F., Yang, J., Yu, H., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700315 · Cited by 44
“Moreover, PGE2 and PGD2, as well as the acetylation of COX-2 triggered by aspirin, actively mobilized the biosynthesis of other proresolving lipid mediators, such as lipoxins and resolvins, to dominate the resolution phase (14, 29, 40).”
BackgroundTrojan, E., Bryniarska, N., Leśkiewicz, M., Regulska, M., Chamera, K., Szuster-Głuszczak, M., Leopoldo, M., Lacivita, E., & Basta‐Kaim, A. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191019170244 · Cited by 44
The Lipoxin A4 Receptor Is Coupled to SHP-2 Activation
Mitchell, D., O'Meara, S. J., Gaffney, A., Crean, J. K. G., Kinsella, B. T., & Godson, C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611004200 · Cited by 43
The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues
Norel, X., & Brink, C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.05.003 · Cited by 44
Menezes‐de‐Lima, O., Kassuya, C. A. L., Nascimento, A. F. Z., Henriques, M. D. G., & Calixto, J. Β. (2006) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.05.016 · Cited by 44
Picard, S., Plante, H., Mancini, J. A., & Borgeat, P. (2005) · Biochemical Journal · doi:10.1042/bj20050669 · Cited by 41
Karp, C. L., Flick, L. M., Yang, R., Uddin, J., & Petasis, N. A. (2005) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.05.015 · Cited by 41
Barnig, C., Lutzweiler, G., Giannini, M., Lejay, A., Charles, A., Meyer, A., & Gény, B. (2022) · Antioxidants · doi:10.3390/antiox11061213 · Cited by 49
“Among leukocytes, neutrophils are key producers of SPMs, including lipoxins, leading members of the SPM family [74].”
BackgroundInfluentialSerhan, C. N., Bäck, M., Chiurchiù, V., Hersberger, M., Mittendorfer, B., Calder, P. C., Waitzberg, D. L., Stoppe, C., Kłęk, S., Martindale, R. G., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202400619r · Cited by 56
“21,22 This switching towards the production of SPMs results in SPM synthesis via pathways that are distinct from those involved in the generation of pro-inflammatory lipid mediators.”
BackgroundSelf-citationFunction of Pro-Resolving Lipid Mediator Resolvin E1 in Type 2 Diabetes
Sima, C., Paster, B. J., & Dyke, T. E. V. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026750 · Cited by 45
Saving Problematic Mucosae: SPMs in Intestinal Mucosal Inflammation and Repair
Quirós, M., & Nusrat, A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.004 · Cited by 47
Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy
Kim, A. S., & Conte, M. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.011 · Cited by 44
Gao, L., Yu, Q., Zhang, H., Wang, Z., Zhang, T., Xiang, J., Yu, S., Zhang, S., Wu, H., Xu, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5071 · Cited by 49
Hung, N. D., Kim, M. R., & Sok, D. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01117.x · Cited by 40
“During the time course of inflammation, the switching of lipid mediator class from pro-inflammatory prostaglandins and leukotrienes to the biosynthesis of anti-inflammatory or pro-resolving lipid mediators, such as lipoxins (Levy et al., 2001; Serhan, 2005a; Serhan and Savill, 2005; Maderna and Godson, 2009), lipoxene…”
BackgroundBouriche, H., Miles, E. A., Selloum, L., & Calder, P. C. (2004) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2004.10.018 · Cited by 40
Finkelstein, J. M., Heemels, M.-T., Shadan, S., & Weiss, U. K. (2014) · Nature · doi:10.1038/510047a · Cited by 44
Lumbroso, D., Soboh, S., Maimon, A., Schif‐Zuck, S., Ariel, A., & Burstyn‐Cohen, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.412281 · Cited by 43
Targeting Angiogenesis via Resolution of Inflammation
Kelly, A. G., & Panigrahy, D. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041172 · Cited by 48
Unified nexus of macrophages and maresins in cardiac reparative mechanisms
Jadapalli, J. K., & Halade, G. V. (2018) · The FASEB Journal · doi:10.1096/fj.201800254r · Cited by 42
“PGE2 and PGD2 have been reported to have a dual, paradoxical role, functioning as a proinflammatory and proresolving mediators, depending on their location (94).”
BackgroundGonzalez, A. L., Dungan, M. M., Smart, C. D., Madhur, M. S., & Doran, A. C. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0284 · Cited by 46
“Clinical trials that treated patients with a combination of EPA and DHA as a means of increasing SPM production yielded mixed results, which has been debated as possibly related to the composition of the omega-3 fatty acid preparations used or the variability of dosing between studies (Sherratt et al., 2023; Sperling…”
InfluentialRasquel-Oliveira, F. S., da Silva, M. D. V., Martelossi-Cebinelli, G., Fattori, V., Casagrande, R., & Verri, W. A., Jr. (2023) · Molecules · doi:10.3390/molecules28135032 · Cited by 49
“As previously mentioned, a lipid mediator class switch is necessary to begin resolution, and that happens by polymorphonuclear cells (PMNs) reducing production of LT and PG and that of increasing SPMs such as LX [14].”
BackgroundPerez-Novo, C. A., Claeys, C., Zele, T. V., Holtapples, G., Cauwenberge, P. V., & Bachert, C. (2006) · American Journal of Rhinology · doi:10.2500/ajr.2006.20.2873 · Cited by 39
Targeting pro-resolution pathways to combat chronic inflammation in COPD.
Bozinovski, S., Anthony, D., & Vlahos, R. (2014) · PubMed · doi:10.3978/j.issn.2072-1439.2014.08.08 · Cited by 47
“Eicosanoids such as lipoxins, resolvins and protectins and the protein termed Annexin A1 are integral to resolution of inflammation, [reviewed in (36-38)]; where there is a class switch of eicosanoid production from chemoattractants (such as the leukotriene LTB4) to pro-resolving mediators (such as lipoxin A4, LXA4) (…”
BackgroundImmunometabolic role of long‐chain omega‐3 fatty acids in obesity‐induced inflammation
Flock, M. R., Rogers, C. J., Prabhu, K. S., & Kris‐Etherton, P. M. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2414 · Cited by 50
“Production of PGE2 results in the downstream synthesis of other eicosanoids, resulting in formation of anti-inflammatory agents via lipid-mediator class switching [109-110].”
Backgroundde Gaetano, M., McEvoy, C. M., Andrews, D. C., Cacace, A., Hunter, J., Brennan, E. P., & Godson, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01488 · Cited by 45
The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer’s Disease
de Wit, N. M., Mol, K., Rodríguez‐Lorenzo, S., de Vries, H. E., & Kooij, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620348 · Cited by 43
Nogueira-Neto, F. D. S., Amorim, R. L., Brigatte, P., Picolo, G., Ferreira, W. A., Gutierrez, V. P., Conceição, I. M., Della-Casa, M. S., Takahira, R. K., Nicoletti, J. L. D. M., et al. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.016 · Cited by 39
“However, increasing evidence indicates that arachidonate-derived mediators, such as prostaglandins and lipoxins, also exert anti-inflammatory function, being involved in inflammatory resolution (Gilroy et al., 2003; Levy et al., 2001).”
BackgroundHutchinson, J. L., Rajagopal, S. P., Sales, K. J., & Jabbour, H. N. (2011) · Reproduction · doi:10.1530/rep-11-0069 · Cited by 45
Lipid Mediator Informatics-Lipidomics: Novel Pathways in Mapping Resolution
Serhan, C. N., Hong, S., & Lü, Y. (2006) · The AAPS Journal · doi:10.1007/bf02854899 · Cited by 46
Self-citationThe 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis
Krönke, G., Reich, N., Scholtysek, C., Akhmetshina, A., Uderhardt, S., Zerr, P., Palumbo, K., Lang, V. R., Dees, C., Distler, O., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200745 · Cited by 46
Conditional Expression of 15-Lipoxygenase-1 Inhibits the Selenoenzyme Thioredoxin Reductase
Yu, M. K., Moos, P. J., Cassidy, P. B., Wade, M. L., & Fitzpatrick, F. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313939200 · Cited by 41
Schulte, F., Asbeutah, A. A., Benotti, P. N., Wood, G. C., Still, C. D., Bistrian, B. R., Hardt, M., & Welty, F. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-75353-6 · Cited by 40
Chaitidis, P., Billett, E. E., O’Donnell, V. B., Bermúdez-Fajardo, A., Fitzgerald, J. C., Kuban, R. ‐., Ungethuem, U., & Kühn, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4821 · Cited by 40
“They are cytosolic proteins and have been implicated in the biosynthesis of proinflammatory leukotrienes (11) or anti-inflammatory lipoxins (12), both of which constitute important mediators of the immune response.”
BackgroundMonk, J. M., Liddle, D. M., Cohen, D. J. A., Tsang, D. H., Hillyer, L. M., Abdelmagid, S. A., Nakamura, M., Power, K. A., David, W. L., & Robinson, L. E. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.01.004 · Cited by 47
Nayak, S., Al‐Ashhab, A., Zilberg, D., & Khozin‐Goldberg, I. (2020) · Biology · doi:10.3390/biology9060119 · Cited by 42
“Studies have also demonstrated that PGE2 production can inhibit 5‐LOX, decreasing the proinflammatory 4‐series LTs (leukotrienes), and at the same time induce 15‐LOX, thus promoting the formation of lipoxins that act to resolve inflammation [43,44].”
BackgroundBioactive Lipid Mediators in the Initiation and Resolution of Inflammation after Spinal Cord Injury
David, S., & López‐Vales, R. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.04.026 · Cited by 42
Chang, M. I., Puder, M., & Gura, K. M. (2012) · Nutrients · doi:10.3390/nu4121828 · Cited by 45
“The switch from a SO IVLE to FO IVLE in was associated with improvement in DHA), and a decrease in serum omega-6 fatty acids (i.e., AA) [114].”
BackgroundInfluentialWhatling, C. A., McPheat, W. L., & Herslöf, M. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1879 · Cited by 39
“In this way, 5-LO switching between different classes of eicosanoid product may be one way in which inflammatory responses can be tightly controlled, ensuring progression from the initiation phase to a resolution phase [23] .”
BackgroundParolini, C. (2023) · Marine Drugs · doi:10.3390/md22010017 · Cited by 41
“…the lipid mediator class switching promotes a shift from the synthesis of prostaglandins (PGs) and leukotrienes (LTs) via 5-lipoxygenase (LOX) in inflammatory exudates to the production of lipoxin A4 via 15-LOX and the following reprogramming of granulocytes to initiate the “resolution phase” [15].”
InfluentialProresolving Lipid Mediators in the Respiratory System
Serhan, C. N., & Levy, B. D. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020924-033209 · Cited by 49
Self-citationRago, B., & Fu, C. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.08.001 · Cited by 39
Wan, M., Soehnlein, O., Tang, X. Y., van der Does, A. M., Smedler, E., Uhlén, P., Lindbom, L., Agerberth, B., & Haeggström, J. Z. (2014) · The FASEB Journal · doi:10.1096/fj.14-251306 · Cited by 40
“(43) demonstrated that during the course of a”
BackgroundInhibition of neogenin fosters resolution of inflammation and tissue regeneration
Schlegel, M., Körner, A., Kaussen, T., Knausberg, U., Gerber, C., Hansmann, G., Jónasdóttir, H. S., Giera, M. A., & Mirakaj, V. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96259 · Cited by 39
“Our data demonstrate the enhanced production of PGD2 and PGE2 in the initial phase, suggesting that the mediator class switch is implemented in the resolution phase (Figure 6A and Supplemental Table 2) (31).”
MethodLipid emulsions – Guidelines on Parenteral Nutrition, Chapter 6
Adolph, M., Heller, A. R., Koch, T., Koletzko, B. V., Kreymann, K. G., Krohn, K., Pscheidl, E., Senkal, M., & Working Group For Developing The Guidelines For Parenteral Nutrition Of The German Association For Nutritional Medicine (2009) · PubMed · doi:10.3205/000081 · Cited by 53
“Their synthesis is favored by the transcriptional up-regulation of neutrophil 15-LO by PGE2 and PGD2, the so-called “eicosanoid switch” [4].”
BackgroundPolyunsaturated fatty acids and their metabolites in the pathobiology of schizophrenia
Das, U. N. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.010 · Cited by 39
Potential role of lipoxin in the management of COVID-19: a narrative review
Batiha, G. E., Al-Gareeb, A. I., Elekhnawy, E., & Al-Kuraishy, H. M. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01070-3 · Cited by 37
“Also, 5% of COVID-19 patients may be seriously affected and need ventilation due to the progression of acute respiratory distress syndrome (ARDS) (Al-Kuraishy et al.”
BackgroundInfluentialGout and NLRP3 Inflammasome Biology
Poulsen, R. C., & Dalbeth, N. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43215 · Cited by 44
“Instead of producing proin fl ammatory prostaglandins and leukotrienes, LOX and COX switch to producing anti-in fl ammatory lipoxins 79 as well as n-3 LCPUFA – derived anti-in fl ammatory or pro-resolving lipid mediators, for example, maresins and resolvins.”
Kaur, S., Lyte, P., Garay, M., Liebel, F. T., Sun, Y., Liu, J., & Southall, M. D. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1145-9 · Cited by 38
Liclican, E. L., Nguyen, V., Sullivan, A. B., & Gronert, K. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5455 · Cited by 36
Self-citationResolvin D2 decreases TLR4 expression to mediate resolution in human monocytes
Croasdell, A., Sime, P. J., & Phipps, R. P. (2016) · The FASEB Journal · doi:10.1096/fj.201600375r · Cited by 39
“Eicosanoids, including both SPMs and proinflammatory mediators, produced in the early stages of inflammation can form feedback loops to promote the shift to anti-inflammatory lipids (43, 44).”
BackgroundHavixbeck, J. J., Rieger, A. M., Churchill, L., & Barreda, D. R. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.02.001 · Cited by 38
Is fatty acid composition of human bone marrow significant to bone health?
Pino, A. M., & Rodríguez, J. P. (2017) · Bone · doi:10.1016/j.bone.2017.12.014 · Cited by 41
Lipoxin A 4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis
Chen, Q., Kuang, X., Yuan, Q.-F., Hao, H., Zhang, T., Huang, Y., & Zhou, X. (2018) · Innate Immunity · doi:10.1177/1753425918785008 · Cited by 36
Neutrophil in Reverse Migration: Role in Sepsis
Ji, J., & Fan, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656039 · Cited by 38
Kowal‐Bielecka, O., Kowal, K., Distler, O., & Gay, S. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0375 · Cited by 36
Lipoxin A4 Counterregulates GM-CSF Signaling in Eosinophilic Granulocytes
Starosta, V., Pazdrak, K., Boldogh, I. R., Svider, T., & Kurosky, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8688 · Cited by 36
“, leukotriene to lipoxin biosynthesis) (5).”
Dakin, S. G., Smith, R. K. W., Heinegård, D. K., Önnerfjord, P., Khabut, A., & Dudhia, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511972 · Cited by 37
“Third, the higher doses of PGE2 can activate resolution of inflammation in tendon fibroblasts via the production of specialized pro-resolving mediators such as lipoxins (50).”
BackgroundNovel Pathways and Endogenous Mediators in Anti-Inflammation and Resolution
Serhan, C. N., & Levy, B. D. (2003) · KARGER eBooks · doi:10.1159/000071558 · Cited by 40
Self-citationTegeder, I., & Geißlinger, G. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0044-7 · Cited by 40
“ATLmimics the actions of native lipoxin A4 that initiates the resolution of inflammation (Levy et al. 2001; McMahon et al. 2001).”
BackgroundResolvins: Endogenously-Generated Potent Painkilling Substances and their Therapeutic Perspectives
Yoo, S., Lim, J. Y., & Hwang, S. W. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311060009 · Cited by 44
“Pro-inflammatory prostaglandins were reported to induce expression of genes that encode enzymes including 15-lipoxygenase (15-LOX), which produce resolving lipids, resolvins and neuroprotectins [14].”
BackgroundResolution of inflammation in arthritis
Schett, G. A. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00768-x · Cited by 41
Chataigner, M., Martin, M., Lucas, C., Pallet, V., Layé, S., Mehaignerie, A., Bouvret, E., Dinel, A., & Joffre, C. (2021) · Nutrients · doi:10.3390/nu13030824 · Cited by 38
Heath, R. J., Klevebro, S., & Wood, T. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020700 · Cited by 39
“The prostaglandin PGE2 promotes the initial inflammatory response but subsequently acts to inhibit LOX to reduce further production of pro-inflammatory prostaglandins [29].”
BackgroundMS-based targeted profiling of oxylipins in COVID-19: A new insight into inflammation regulation
Biagini, D., Franzini, M., Oliveri, P., Lomonaco, T., Ghimenti, S., Bonini, A., Vivaldi, F. M., Macera, L., Balas, L., Durand, T., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.021 · Cited by 37
“, resolvins, protectins, and maresins) is critical for inflammation resolution [39].”
Application of proteomics to neutrophil biology
Luerman, G. C., Uriarte, S. M., Rane, M. J., & McLeish, K. R. (2009) · Journal of Proteomics · doi:10.1016/j.jprot.2009.06.013 · Cited by 37
“Resolution is initiated by release of anti-inflammatory cytokines by macrophages, including IL-10, IL-13, and transforming growth factor (TGF)-β, and lipid-derived mediators of resolution (lipoxins, protectins, and resolvins) by vascular endothelial cells and macrophages [14].”
BackgroundDas, U. N. (2013) · Clinical Lipidology · doi:10.2217/clp.13.32 · Cited by 37
Inflammatory mediators generated at the site of inoculation of Loxosceles gaucho spider venom
Barbaro, K. C., Lira, M. S., de Araújo, C. A. A., Pareja‐Santos, A., Távora, B. D. C. L. F., Prezotto-Neto, J. P., Kimura, L. F., Lima, C., Lopes‐Ferreira, M., & Santoro, M. L. (2010) · Toxicon · doi:10.1016/j.toxicon.2010.06.022 · Cited by 35
Bannenberg, G. L. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.57 · Cited by 39
“The generation of LXA4 upon its turn can activate the resolution of inflammation[108].”
BackgroundPathophysiological effects of glucocorticoids on nasal polyps: an update
Benson, M. (2005) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200502000-00007 · Cited by 37
Everts, P. A., Mazzola, T., Mautner, K., Randelli, P. S., & Podesta, L. (2022) · Biomedicines · doi:10.3390/biomedicines10112933 · Cited by 34
Bäck, M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108439 · Cited by 36
Zaid, A. K. M. A., & Ariel, A. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115204 · Cited by 36
Bioanalytical insights into mediator lipidomics
Kasuga, K., Suga, T., & Mano, N. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.02.011 · Cited by 37
Dexamethasone induces ω3-derived immunoresolvents driving resolution of allergic airway inflammation
Pyrillou, K., Chairakaki, A.-D., Tamvakopoulos, C., & Andreakos, E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.04.004 · Cited by 34
Altered tissue specialized pro-resolving mediators in chronic rhinosinusitis
Vickery, T. W., Armstrong, M., Kofonow, J. M., Robertson, C. E., Kroehl, M., Reisdorph, N. A., Ramakrishnan, V. R., & Frank, D. N. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102218 · Cited by 40
“These compounds are likely not the most informative for characterizing CRS subtypes since they facilitate both acute inflammation and pro-resolving actions though lipid mediator class-switching.[42, 43]”
BackgroundBlaho, V. A., Mitchell, W., & Brown, C. R. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23371 · Cited by 34
Long-chain polyunsaturated fatty acids and inflammation
Calder, P. C. (2006) · Scandinavian Journal of Food & Nutrition · doi:10.1080/17482970601066389 · Cited by 43
Pashover‐Schallinger, E., Aswad, M., Schif‐Zuck, S., Shapiro, H., Singer, P., & Ariel, A. (2012) · The FASEB Journal · doi:10.1096/fj.11-194894 · Cited by 37
“Key Words: chemokine receptors apoptotic cell clearance acute immune responses leukocytes During the active resolution of inflammation (1, 2), immune response elements are eliminated (3).”
Background
Metadata
- Authors
- Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Serhan, Charles N.
- Venue
- Nature Immunology
- Published
- 2001-07
- Volume
- 2
- Issue
- 7
- Pages
- 612-619
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W1497700962
- Cited by
- 1,453
- References
- 42
- Citations by year
- 2026: 48 · 2025: 60 · 2024: 61 · 2023: 74 · 2022: 74 · 2021: 81 · 2020: 76 · 2019: 64 · 2018: 69 · 2017: 62 · 2016: 62 · 2015: 63 · 2014: 62 · 2013: 69 · 2012: 60
- FWCI
- 33.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08hl003788-04)
- National Heart, Lung, and Blood Institute (K08 HL 03788)
- National Institute of General Medical Sciences (GM 38765)
- National Institute of Allergy and Infectious Diseases (F32AI010389, F32-AI10389)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-50305, P01DK050305, K01DK060583)
- National Institute of Dental and Craniofacial Research (P01 DE 13499, P01DE013499)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- lipid mediators, acute inflammation, inflammation resolution, leukotrienes, prostaglandins, lipoxins, eicosanoid biosynthesis, neutrophil recruitment, lipoxin A4, leukotriene B4, 5-lipoxygenase, 15-lipoxygenase, prostaglandin E2, exudate, anti-inflammatory signaling
- MeSH terms
- Animals, Arachidonate 15-Lipoxygenase, Base Sequence, Humans, Hydroxyeicosatetraenoic Acids, Leukotriene B4, Lipids, Male, Mice, Inbred BALB C, Molecular Sequence Data, Neutrophils, Pleural Effusion, RNA, Messenger, Dinoprostone, Molecular Structure, Signal Transduction, DNA, Complementary, Lipoxins, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.